selegiline has been researched along with Depression in 37 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (24.32) | 18.7374 |
| 1990's | 9 (24.32) | 18.2507 |
| 2000's | 8 (21.62) | 29.6817 |
| 2010's | 8 (21.62) | 24.3611 |
| 2020's | 3 (8.11) | 2.80 |
| Authors | Studies |
|---|---|
| Dedecengiz, E; Erikci, A; Gokhan-Kelekci, N; Kaynak, FB; Salgin-Goksen, U; Tel, BC; Telli, G; Ucar, G; Yelekci, K | 1 |
| Han, Y; Huang, S; Liu, K; Liu, S; Xiong, F | 1 |
| Gómez-Galán, M; Henning, L; Lindskog, M; Srivastava, I; Vazquez-Juarez, E | 1 |
| Correa, M; Reynolds, S; Salamone, JD; Tripodi, G; Yohn, SE | 1 |
| Madhav, NVS; Tyagi, Y | 1 |
| Baqi, Y; Correa, M; Khan, B; Lee, CA; Makriyannis, A; Müller, CE; Nowak, V; Nunes, EJ; Pandit, S; Randall, PA; Salamone, JD; Shah, P; Vemuri, VK; Yohn, SE | 1 |
| Hallan, SS; Mehra, NK; Mishra, N; Prakash, A; Rashid, M; Singh, D | 1 |
| Alijanpour, S; Amini-Khoei, H; Amiri, S; Haj-Mirzaian, A; Mehdizadeh, M; Mohammadi-Asl, A; Olson, CO; Rahimi-Balaei, M; Rastegar, M; Razmi, A; Zarrindast, MR | 1 |
| Keller, D | 1 |
| Holford, NH; Nutt, JG; Vu, TC | 2 |
| Robinson, DS | 1 |
| Herkes, GK; McKay, D; Meagher, LJ; Needham, M | 1 |
| Morgan, PT | 1 |
| Pae, CU; Patkar, AA; Zarzar, M | 1 |
| Knoll, J | 3 |
| Gershon, S; Mann, J | 1 |
| Calne, DB; Chuang, LW; Eisler, T; Karoum, F; Klein, DF; Liebowitz, MR; Quitkin, FM; Wyatt, RJ | 1 |
| Standaert, DG; Stern, MB | 1 |
| Olanow, CW | 1 |
| Asnis, J; Patel, SV; Tariot, PN | 1 |
| Kuhn, W; Müller, T | 1 |
| Alexander, B; Ritter, JL | 1 |
| Hauser, RA; Zesiewicz, TA | 1 |
| Chouinard, S; Fahn, S | 1 |
| Ballering, LA; Jansen Steur, EN | 1 |
| Marsh, C; Preskorn, SH; Shad, MU | 1 |
| Ball, J | 1 |
| Miyoshi, K | 1 |
| Mendlewicz, J; Youdim, MB | 1 |
| Follender, AB; Hughes, PL; Jermain, DM | 1 |
| Kraus, P; Kuhn, W; Przuntek, H | 1 |
| Eisenhofer, G; Goldstein, DS; Keiser, HR; Kopin, IJ; Murphy, DL; Stull, R; Sunderland, T | 1 |
| Agnoli, A; Baronti, F; Denaro, A; Ruggieri, S; Stocchi, F | 1 |
| Baas, H; Fischer, PA | 1 |
7 review(s) available for selegiline and Depression
| Article | Year |
|---|---|
Transdermal selegiline.
Topics: Administration, Cutaneous; Antidepressive Agents; Depression; Drug Interactions; Food-Drug Interactions; Humans; Monoamine Oxidase Inhibitors; Selegiline | 2007 |
Update on the management of Parkinson's disease.
Topics: Depression; Diagnosis, Differential; Dopamine Agents; Hallucinations; Humans; Levodopa; Parkinson Disease; Selegiline | 1993 |
The clinical potential of Deprenyl in neurologic and psychiatric disorders.
Topics: Adult; Aged; Alzheimer Disease; Amyotrophic Lateral Sclerosis; Antidepressive Agents; Antipsychotic Agents; Child; Clinical Trials as Topic; Cross-Over Studies; Depression; Double-Blind Method; Humans; Mental Disorders; Middle Aged; Monoamine Oxidase Inhibitors; Narcolepsy; Nervous System Diseases; Neuroprotective Agents; Nootropic Agents; Parkinson Disease, Secondary; Schizophrenia; Selegiline; Supranuclear Palsy, Progressive; Tourette Syndrome; Treatment Outcome | 1996 |
Retrospective study of selegiline-antidepressant drug interactions and a review of the literature.
Topics: Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Antiparkinson Agents; Bupropion; Comorbidity; Depression; Drug Interactions; Humans; Monoamine Oxidase Inhibitors; Parkinson Disease; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Selegiline | 1997 |
[Parkinson's disease].
Topics: Antiparkinson Agents; Depression; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Selective Serotonin Reuptake Inhibitors; Selegiline | 2001 |
Antiaging compounds: (-)deprenyl (selegeline) and (-)1-(benzofuran-2-yl)-2-propylaminopentane, [(-)BPAP], a selective highly potent enhancer of the impulse propagation mediated release of catecholamine and serotonin in the brain.
Topics: Aging; Alzheimer Disease; Animals; Benzofurans; Brain; Catecholamines; Depression; Humans; Neuroprotective Agents; Parkinson Disease; Propylamines; Selegiline; Serotonin | 2001 |
The facilitation of dopaminergic activity in the aged brain by (-)deprenyl. A proposal for a strategy to improve the quality of life in senescence.
Topics: Aged; Aging; Animals; Brain; Depression; Dopamine; Geriatrics; Humans; Male; Monoamine Oxidase Inhibitors; Parkinson Disease; Phenethylamines; Quality of Life; Rats; Selegiline; Sexual Behavior | 1985 |
4 trial(s) available for selegiline and Depression
| Article | Year |
|---|---|
Sertraline for the treatment of depression in Parkinson's disease.
Topics: 1-Naphthylamine; Aged; Antidepressive Agents, Second-Generation; Antiparkinson Agents; Depression; Drug Interactions; Drug Therapy, Combination; Humans; Parkinson Disease; Pilot Projects; Prospective Studies; Selective Serotonin Reuptake Inhibitors; Selegiline; Sertraline; Severity of Illness Index; Treatment Outcome | 1997 |
Experience with tranylcypromine in early Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Depression; Erectile Dysfunction; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline; Sleep Initiation and Maintenance Disorders; Time Factors; Tranylcypromine; Tyramine | 1998 |
Combined and selective monoamine oxidase inhibition in the treatment of depression in Parkinson's disease.
Topics: Adult; Aged; Benzamides; Cognition; Depression; Drug Combinations; Female; Humans; Male; Medical Records; Middle Aged; Moclobemide; Monoamine Oxidase Inhibitors; Movement; Parkinson Disease; Selegiline | 1999 |
Therapeutic efficacy of R-(-)-deprenyl as adjuvant therapy in advanced parkinsonism.
Topics: Aged; Clinical Trials as Topic; Depression; Disability Evaluation; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Phenethylamines; Selegiline; Thioxanthenes | 1987 |
26 other study(ies) available for selegiline and Depression
| Article | Year |
|---|---|
New 2-Pyrazoline and Hydrazone Derivatives as Potent and Selective Monoamine Oxidase A Inhibitors.
Topics: Animals; Antidepressive Agents; Depression; Hep G2 Cells; Humans; Hydrazones; Mice; Molecular Docking Simulation; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Protein Binding; Pyrazoles; Structure-Activity Relationship | 2021 |
The novel design of an intelligent anti-depression transdermal drug delivery system.
Topics: Administration, Cutaneous; Animals; Antidepressive Agents; Depression; Disease Models, Animal; Drug Delivery Systems; Hippocampus; Humans; Rats; Selegiline | 2023 |
Blocking Astrocytic GABA Restores Synaptic Plasticity in Prefrontal Cortex of Rat Model of Depression.
Topics: Animals; Astrocytes; Atrophy; Depression; Disease Models, Animal; gamma-Aminobutyric Acid; Long-Term Potentiation; Male; Neuronal Plasticity; Prefrontal Cortex; Rats, Sprague-Dawley; Receptors, GABA; Selegiline | 2020 |
The monoamine-oxidase B inhibitor deprenyl increases selection of high-effort activity in rats tested on a progressive ratio/chow feeding choice procedure: Implications for treating motivational dysfunctions.
Topics: Animal Feed; Animals; Antidepressive Agents; Behavior, Animal; Choice Behavior; Conditioning, Operant; Depression; Dopamine; Feeding Behavior; Male; Models, Animal; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Motivation; Nucleus Accumbens; Rats; Rats, Sprague-Dawley; Selegiline | 2018 |
Design of selegiline-loaded bio-nanosuspension for the management of depression using novel bio-retardant from
Topics: Chemistry, Pharmaceutical; Depression; Drug Delivery Systems; Drug Liberation; Manilkara; Nanoparticles; Particle Size; Plant Extracts; Polymers; Selegiline; Solubility; Solvents; Suspensions; X-Ray Diffraction | 2019 |
The VMAT-2 inhibitor tetrabenazine affects effort-related decision making in a progressive ratio/chow feeding choice task: reversal with antidepressant drugs.
Topics: Animals; Antidepressive Agents; Benzazepines; Benzophenones; Bupropion; Cannabinoid Receptor Antagonists; Choice Behavior; Depression; Dopamine Antagonists; Drug Evaluation, Preclinical; Feeding Behavior; Male; Nitrophenols; Pyrazoles; Rats, Sprague-Dawley; Salicylamides; Selegiline; Tetrabenazine; Tolcapone; Vesicular Monoamine Transport Proteins; Xanthines | 2014 |
Pharmacological evaluation of nasal delivery of selegiline hydrochloride-loaded thiolated chitosan nanoparticles for the treatment of depression.
Topics: Administration, Intranasal; Animals; Antidepressive Agents; Chitosan; Depression; Disease Models, Animal; Drug Evaluation, Preclinical; Male; Nanoparticles; Rats; Rats, Wistar; Selegiline | 2016 |
Involvement of D1 and D2 dopamine receptors in the antidepressant-like effects of selegiline in maternal separation model of mouse.
Topics: Analysis of Variance; Animals; Antidepressive Agents; Depression; Disease Models, Animal; Dopamine Agents; Dose-Response Relationship, Drug; Exploratory Behavior; Female; Food Preferences; Grooming; Male; Maternal Deprivation; Mice; Motivation; Receptors, Dopamine D1; Receptors, Dopamine D2; Selegiline; Swimming | 2016 |
MAO inhibitors.
Topics: Depression; Humans; Indans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline | 2011 |
Progression of motor and nonmotor features of Parkinson's disease and their response to treatment.
Topics: Antiparkinson Agents; Cognition Disorders; Depression; Disability Evaluation; Disease Progression; Drug Substitution; Drug Therapy, Combination; Gait Disorders, Neurologic; Humans; Hypokinesia; Linear Models; Motor Activity; Nonlinear Dynamics; Parkinson Disease; Patient Dropouts; Postural Balance; Predictive Value of Tests; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Retrospective Studies; Selegiline; Sensation Disorders; Severity of Illness Index; Surveys and Questionnaires; Time Factors; Tocopherols; Treatment Outcome; Tremor | 2012 |
Disease progress and response to treatment as predictors of survival, disability, cognitive impairment and depression in Parkinson's disease.
Topics: Adult; Aged; Analysis of Variance; Antiparkinson Agents; Chi-Square Distribution; Cognition; Cognition Disorders; Depression; Disability Evaluation; Disease Progression; Humans; Kaplan-Meier Estimate; Middle Aged; Parkinson Disease; Patient Dropouts; Predictive Value of Tests; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Assessment; Risk Factors; Selegiline; Severity of Illness Index; Time Factors; Tocopherols; Treatment Outcome | 2012 |
Monoamine oxidase inhibitors: a new generation.
Topics: Administration, Cutaneous; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Monoamine Oxidase Inhibitors; Selegiline | 2002 |
Parkinsonism-hyperpyrexia syndrome: the role of electroconvulsive therapy.
Topics: Acetaminophen; Acyclovir; Analgesics, Non-Narcotic; Analgesics, Opioid; Anti-Anxiety Agents; Anti-Bacterial Agents; Anti-Inflammatory Agents; Antiparkinson Agents; Antiviral Agents; Anxiety; Carbidopa; Ceftriaxone; Cervical Vertebrae; Depression; Dexamethasone; Diazepam; Doxepin; Electroconvulsive Therapy; Humans; Levodopa; Male; Middle Aged; Neuroleptic Malignant Syndrome; Oxycodone; Pain; Parkinson Disease; Selegiline; Spinal Injuries | 2006 |
Treatment-resistant depression: response to low-dose transdermal but not oral selegiline.
Topics: Administration, Cutaneous; Aged; Depression; Drug Administration Routes; Drug Resistance; Humans; Male; Monoamine Oxidase Inhibitors; Selegiline | 2007 |
Deprenyl (selegiline): the history of its development and pharmacological action.
Topics: Aging; Animals; Brain; Depression; Dopamine; Drug Evaluation; History, 20th Century; Humans; Male; Monoamine Oxidase Inhibitors; Neurons; Parkinson Disease; Phenethylamines; Rats; Rats, Inbred Strains; Selegiline; Sexual Behavior | 1983 |
L-deprenyl, a selective monoamine oxidase type-B inhibitor in endogenous depression.
Topics: Adult; Blood Platelets; Depression; Drug Evaluation; Female; Humans; Middle Aged; Monoamine Oxidase; Phenethylamines; Selegiline | 1980 |
Metabolism of (-) deprenyl to amphetamine and methamphetamine may be responsible for deprenyl's therapeutic benefit: a biochemical assessment.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adult; Amphetamines; Biogenic Amines; Carbidopa; Depression; Drug Combinations; Female; Humans; Levodopa; Male; Methamphetamine; Middle Aged; Monoamine Oxidase; Parkinson Disease; Phenethylamines; Selegiline; Tyramine | 1982 |
A 61-year-old man with Parkinson's disease.
Topics: 1-Naphthylamine; Antiparkinson Agents; Carbidopa; Depression; Dopamine Agents; Drug Interactions; Drug Therapy, Combination; Family Practice; Humans; Levodopa; Male; Middle Aged; Neurology; Neuroprotective Agents; Parkinson Disease; Selegiline; Sertraline; Vitamin E | 1996 |
L-Deprenyl augmentation of fluoxetine in a patient with Huntington's disease.
Topics: Adult; Anticonvulsants; Antidepressive Agents, Second-Generation; Attention; Carbamazepine; Depression; Drug Interactions; Drug Therapy, Combination; Expressed Emotion; Female; Fluoxetine; Humans; Huntington Disease; Impulsive Behavior; Monoamine Oxidase Inhibitors; Movement; Selegiline; Violence | 1996 |
The economic consequences of a drug-drug interaction.
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Depression; Drug Interactions; Female; Fluoxetine; Haloperidol; Health Care Costs; Humans; Olanzapine; Parkinson Disease; Pirenzepine; Selegiline; Trihexyphenidyl | 2001 |
Current advances in Parkinson's disease.
Topics: Antidepressive Agents; Antiparkinson Agents; Benzothiazoles; Brain Stem; Catechols; Depression; Dopamine Agonists; Humans; Levodopa; Nitriles; Parkinson Disease; Pramipexole; Selegiline; Thiazoles | 2001 |
Anti-depressant potentiation of 5-hydroxytryptophan by L-deprenyl, an MAO "type B" inhibitor.
Topics: Adult; Antidepressive Agents; Depression; Drug Synergism; Drug Therapy, Combination; Female; Humans; Informed Consent; Male; Middle Aged; Phenethylamines; Selegiline; Serotonin | 1978 |
Potential fluoxetine-selegiline interaction.
Topics: Aged; Ataxia; Depression; Drug Interactions; Female; Fluoxetine; Humans; Parkinson Disease; Selegiline | 1992 |
The effect of R-(-)-deprenyl in de novo parkinsonian patients pretreated with levodopa and decarboxylase inhibitor correlated to depression and MHPG, HIAA and HVA levels in the cerebrospinal fluid.
Topics: Benserazide; Depression; Double-Blind Method; Drug Therapy, Combination; Female; Glycols; Homovanillic Acid; Humans; Hydrazines; Hydroxyindoleacetic Acid; Levodopa; Male; Methoxyhydroxyphenylglycol; Middle Aged; Motor Activity; Parkinson Disease; Phenethylamines; Selegiline | 1989 |
Simultaneous liquid-chromatographic determination of 3,4-dihydroxyphenylglycol, catecholamines, and 3,4-dihydroxyphenylalanine in plasma, and their responses to inhibition of monoamine oxidase.
Topics: Alzheimer Disease; Animals; Catecholamines; Chromatography, Liquid; Depression; Dihydroxyphenylalanine; Dogs; Glycols; Humans; Methoxyhydroxyphenylglycol; Monoamine Oxidase Inhibitors; Posture; Quality Control; Selegiline; Tranylcypromine | 1986 |
The role of MAO-b inhibitors in the treatment of Parkinson's disease.
Topics: Adult; Aged; Depression; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Phenethylamines; Selegiline | 1986 |